HIV/AIDS Vaccines

Some propelled stage clinical trials of HIV immunization are continuous. Despite the fact that the production of a compelling HIV-1 antibody remains a tremendous test, the proceeding with advance in these zones gives motivation to be idealistic about our definitive capacity to control the spread of AIDS. Development of a HIV/AIDS immunization has been ease back on the grounds that established ways to deal with antibody improvement have not yielded an antibody.

  • Age acceleration effects due to HIV infection
  • Attenuated Virus Vaccines in HIV Infection
  • HIV stems vaccination
  • HIV Vaccine development from Animal Models
  • Microbicides for sexually Transmitted Diseases
  • Recombinant vector vaccine
  • Others

Related Conference of HIV/AIDS Vaccines

October 22-23, 2018

30th World Congress on Vaccines and Immunization

Osaka, Japan
December 06-07, 2018

International Congress on Vaccines & Immunology

Amsterdam, Netherlands
March 18-19, 2019

33rdAnnual Vaccines & Vaccination Congress

New York, USA
May 20-21, 2019

35th World Vaccines & Immunization Congress

Tokyo, Japan

HIV/AIDS Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in